Rapamycin: something old, something new, sometimes borrowed and now renewed (Q36922923)

17 August 2017

1 reference

title

Rapamycin: something old, something new, sometimes borrowed and now renewed (English)

1 reference

17 August 2017

1 reference

Hartford CM

1 reference

17 August 2017

Ratain MJ

series ordinal

1 reference

17 August 2017

language of work or name

English

0 references

publication date

29 August 2007

1 reference

Clinical Pharmacology & Therapeutics

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

381-388

1 reference

TOR signaling in growth and metabolism

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Growing roles for the mTOR pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Recent advances in the regulation of the TOR pathway by insulin and nutrients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Targeting the molecular target of rapamycin (mTOR).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

mTOR signaling: implications for cancer and anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Predicted mechanisms of resistance to mTOR inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycins: mechanism of action and cellular resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin for immunosuppression in organ allografting.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Preclinical evaluation of a new potent immunosuppressive agent, rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Mechanism of action of the immunosuppressant rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

From beach to bedside: history of the development of sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Clinical pharmacokinetics of sirolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Blood distribution of rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus: the evidence for clinical pharmacokinetic monitoring.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

1 reference

7 January 2021

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Clinical pharmacokinetics of everolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Role of the CDKN2A locus in patients with multiple primary melanomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus--challenging current perspectives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Potential therapeutic applications of autophagy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin successfully treats post-transplant autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Efficacy of rapamycin in patient with juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin Enhances the Number of Alloantigen-Induced Human CD103+CD8+ Regulatory T Cells In Vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Acceleration of apoptosis in CD4+CD8+ thymocytes by rapamycin accompanied by increased CD4+CD25+ T cells in the periphery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

mTOR regulates cell survival after etoposide treatment in primary AML cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Antileukemic activity of rapamycin in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin attenuates load-induced cardiac hypertrophy in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin ameliorates experimental autoimmune myocarditis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100317

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100317

1 reference

17 August 2017

1 reference